• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- Mpox cases spiking in 10 African nations

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/mpox/mpox-cases-spiking-10-african-nations

Mpox cases spiking in 10 African nations



Stephanie Soucheray, MA


45 minutes ago.

Mpox
In a report released this week, the Africa Centers for Disease Control and Prevention (AfricaCDC) said mpox cases have risen by 160% on the continent this year compared with 2023.

While 96% of cases have been recorded in the Democratic Republic of the Congo (DRC), several other African countries this week have reported new outbreaks, including Kenya, Cote d’Ivoire, and the Central African Republic (CAR).

As of July 28, 2024, a total of 14,250 cases (2,745 confirmed; 11,505 suspected) and 456 deaths (case fatality rate [CFR]: 3.2%) have been recorded in 10 African nations, including Burundi, Cameroon, CAR, Congo, DRC, Ghana, Liberia, Nigeria, Rwanda, and South Africa.

"While mpox is moderately transmissible and usually self-limiting, the case fatality rate has been much higher on the African continent compared to the rest of the world,” the AfricaCDC said.

While mpox is moderately transmissible and usually self-limiting, the case fatality rate has been much higher on the African continent compared to the rest of the world

Though safe and effective mpox vaccines and antivirals are widely available in the United States and Europe, their use is uncommon in Africa.

Clade 1b spreading in DRC

Some of the cases have been caused by what researchers are calling "clade 1b," a new mpox lineage identified in the DRC last year that is highly transmissible and has a higher CFR than clade 2, which swept across the globe in 2022 among men who have sex with men in a sexual transmission pattern. The CFR for clade 2 is less than 1%, while 1b’s CFR is roughly 6%.

There is evidence in the DRC that clade 1b is spreading both through household transmission and sexual transmission, with clade 1b and clade 2 outbreaks occurring simultaneously.

Currently the DRC outbreak stands at 13,791 cases (2,628 confirmed; 11,163 suspected) and 450 deaths (CFR: 3.3%), with cases detected in 25 of 26 provinces. Males accounted for 73% of all cases reported, and children under 15 years accounted for 68% of cases and 85% of deaths.

Earlier this week, the European Centre for Disease Control (ECDC) issued a statement announcing that, for now, the risk of clade 1b spread to Europe remains low.

"ECDC is engaging with our partners in Africa in their efforts to contain this outbreak for the benefit of all those affected, prevent this new variant from spreading any further and reinforce future preparedness and response capabilities," said Pamela Rendi-Wagner, MD, MSc, director of ECDC, in a statement.

Last week, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would launch a clinical trial of the Bavarian Nordic mpox vaccine in the DRC to see if the vaccine protects against infection prophylactically.​
 
Back
Top Bottom